It is well known that in CSF from AD patients, tau levels are increased, while Aβ42 levels are decreased, and a combination of T‐tau, P‐tau, and Aβ42 is commonly used as biomarker for diagnosis of AD 3. This evidence concerns the gene MAPT and Alzheimer disease.